Eric Lefkofsky.

Eric Lefkofsky is the Chief Executive Officer and the Co-founder of Tempus. Tempus is a technological research company that uses an operating system to fight cancer. Eric is also a co-starter of Lightbank firm that deals in financial investment in troublesome technologies. Eric Lefkofsky is also one of the initiators of Groupon, and he is the chairman of the organization.

Eric Lefkofsky is a trustee of the Art Institute of Chicago, the Lurie Children’s Hospital in Chicago, World Business Chicago and The Museum of Science and Industry. Eric works as the Chairman of the Board of Trustees of Chicago’s Steppenwolf Theatre Company. In collaboration with his spouse Liz, he started the Lefkofsky Family Foundation with a dream of advancing and impacting enterprises in essential human rights, culture, art, medicine and education that improve livelihood in the societies they offer services.

Tempus is one of the companies that developed at a very high rate. It took about three years from its launch for it to be among the best ten health tech startup in rank. Tempus company associates with the majority of the National Cancer Institute’s wide-ranging cancer hubs in the United States. The company’s services include cancer testing, RNA sequencing of growths, organoid beliefs of lump cells with drug scanning, pathology and therapeutic imaging and liquid operation of cell-free DNA.

Recently, Tempus company appeared in the Eric Topol’s list that features annually. In this list, Dr. Topol considers the technological developments that have hit the headlines over that year. These technologies should have potential to better and transform medicine in future.

Tempus Labs was among the mentioned innovative technologies. Among them were duo biotechnologies, gene editing, and gene therapy, that are used to treat diseases that were considered terminal formerly. The approval of Voretigene neparvovec-rzyl by the U.S Food and Drug Administration in 2017 helped in the treatment of the rare illness that causes blindness by aiming at changes in a particular gene.
Researchers at Stanford University invented a deep-learning system in the skin cancers technology list. The device helps in investigating skin cancer that corresponds the doctor’s abilities to detect both benign lesions and cancerous correctly.

The list also contained a pathogen sequencing expertise that allows rapid sequencing of disease causing cells’ genomes. The technology achieves this by use of apparatuses that can be employed amidst of an epidemic and result to quick public health reaction.

Visit More : www.facebook.com/eplefkofsky/

Leave a Reply

Your email address will not be published. Required fields are marked *